Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 5Neoplasms 1Endometrial Hyperplasia 1Endometrial Adenocarcinoma 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Taxes 3Paclitaxel 3Carboplatin 3Immunoglobulin G 2Disulfides 2Bevacizumab 2trastuzumab biosimilar HLX02 1temsirolimus 1nintedanib 1linrodostat 1ixabepilone 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Gemcitabine 1Epothilones 1Cisplatin 1Brachytherapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Adenocarcinoma × Medroxyprogesterone Acetate × Clear all
NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

GOG Foundation

Phase 2 Completed
75 enrolled 6 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡